Dirucotide: Completed Phase III enrollment

BioMS completed enrollment of about 510 patients expressing HLA-DR2 and/or HLA- DR4 genes in the double-blind, U.S., Phase III MAESTRO-03 trial comparing intravenous MBP8298 vs. placebo given every 6...